Forrest Nollaig purchased $100K of AMRZ

Forrest Nollaig (Chief Mktg & Corp Affairs Off) purchased 2,000 shares of Amrize Ltd (AMRZ) at $50.25 ($0.10M total) on 2026-05-22.

Original reporting
SEC EDGAR · Forrest Nollaig
Published May 26, 2026, 5:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 5:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AMRZ
Bullish
medium confidence
Mentioned
$AMRZ
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMRZBullishMed
01

Why it matters

This disclosure may slightly improve sentiment toward AMRZ, but it does not constitute a fundamental catalyst (no earnings, deal, or regulatory update provided).

02

Market read

Traders may use the insider buy as a minor bullish input, but expect limited price reaction absent additional news.

03

What to watch

Transaction size (~$100.5k) is relatively small; without follow-on buys/sells or guidance, signal strength is likely weak.

Relevance 7/10Timing: Immediate (filed 2026-05-26; trade date 2026-05-22) for short-term sentiment checks.

Background

The filing is an SEC Form 4 insider transaction: Forrest Nollaig (Chief Mktg & Corp Affairs Officer) bought AMRZ shares in an open-market purchase, not under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$AMRZBullishMedium confidence
Context

Amrize Ltd (AMRZ) disclosed an officer open-market purchase of 2,000 shares at $50.25 on 2026-05-22 via SEC Form 4.

Expected impact

Likely limited near-term impact; could add incremental support if market treats it as confidence signal.

Evidence & confidence

Form 4 shows direct officer buying and no 10b5-1 plan, yet the article provides no operational catalyst or size context beyond ~$100.5k.

Market effects

Minimal—this is company-specific insider activity with no stated sector-wide catalyst.

None indicated; no geographic or cross-border developments mentioned.

None indicated; transaction is a routine SEC insider disclosure.

Counterpoint

Insider buys can be routine liquidity/compensation-related actions and may not reflect new fundamentals, especially without additional corroborating news.

Key entities

  • Amrize Ltd

    AMRZ insider disclosed an open-market purchase of 2,000 shares at $50.25 on 2026-05-22.

  • Forrest Nollaig

    Chief Mktg & Corp Affairs Officer; purchased 2,000 AMRZ shares directly.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMRZHigh

Jefferies downgrades Amrize stock rating on margin concerns

Jefferies downgraded Amrize (NYSE:AMRZ) to Underperform, cutting its price target to $35.20 from $42.80. Analyst Glynis Johnson cited margin concerns due to rising costs and tough comparisons in 2027. The stock is down 23% year-to-date. Jefferies forecasts continued cost pressures will impact margins. Amrize reported Q3 2026 earnings beating profit estimates but missing revenue targets.

$BETAMed

5 Stocks Analysts Just Downgraded

Wall Street analysts downgraded five stocks: BETA Technologies (BETA), TransUnion (TRU), Molson Coors (TAP), Amrize (AMRZ), and another. Downgrades cited delivery delays, slower growth, soft demand, and cost pressures. BETA's Q3 revenue doubled, but deliveries were delayed. TransUnion's revenue rose 12.2%, but margins slipped. Molson Coors saw net sales fall 1.6% and lowered earnings guidance. Amrize adjusted EBITDA and revenue forecasts due to cost inflation.

Med

Amrize Q3 2026 slides: pricing drives margins amid volume headwinds

Amrize reported Q3 2026 revenues of $3.77B, up 2.2% YoY, with net income rising 3.3% to $558M. Pricing initiatives and acquisitions offset volume declines due to weather. Building Materials segment grew 1.8%, while Building Envelope faced challenges. Guidance updated to $12.2B-$12.4B in revenue and $2.95B-$3.05B in adjusted EBITDA for 2026.

$AMRZMed

DA Davidson raises Amrize stock price target to $43 on mixed Q3

DA Davidson raised its price target for Amrize (NYSE:AMRZ) to $43, citing mixed Q3 results with strong Building Materials offset by Building Envelope pressure. The stock is up 5.5% weekly but down 22% in six months. Amrize guided below consensus but beat EPS estimates by 2.06% while missing revenue by 0.95%. DA Davidson maintains a Neutral rating, awaiting more execution visibility.

$AMRZHighAI 9/10

What Amrize (AMRZ) Said on Its Q3 Earnings Call

Amrize (AMRZ) reported Q3 revenue growth of 1.8% to $2.8B in Building Materials and 3.6% to $929M in Building Envelope. Adjusted EBITDA rose 2.7% in Building Materials but fell 14.6% in Building Envelope due to higher costs. The company expects price-over-cost positivity in Building Envelope by 2027. Amrize reaffirmed its 2026 outlook, targeting $12.2B-$12.4B in revenue and $2.95B-$3.05B in EBITDA. It returned $1.1B to shareholders through dividends and repurchases.

$AMRZMed

Amrize Ltd (AMRZ) Q3 2026 Earnings Call Highlights: Pricing Power Drives Growth

Amrize Ltd (AMRZ) reported Q3 2026 earnings, with revenue and EBITDA guidance updated to $12.2-$12.4B and $2.95-$3.05B. Cement volumes fell 4.2% YoY due to weather, while building envelope EBITDA declined 14.6% from inflation. Price-cost positivity in building envelope delayed to 2027. CEO Jan Jenisch expects 2027 growth but cites inflation and interest rate uncertainties. Free cash flow conversion below 50% target due to higher CapEx.